Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Accumulated Expenses: 2020-2024

Historic Other Accumulated Expenses for Beam Therapeutics (BEAM) over the last 5 years, with Dec 2024 value amounting to $7.8 million.

  • Beam Therapeutics' Other Accumulated Expenses rose 5.28% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 5.28%. This contributed to the annual value of $7.8 million for FY2024, which is 72.73% down from last year.
  • As of FY2024, Beam Therapeutics' Other Accumulated Expenses stood at $7.8 million, which was down 72.73% from $28.6 million recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' Other Accumulated Expenses registered a high of $28.6 million during FY2023, and its lowest value of $4.2 million during FY2020.
  • Over the past 3 years, Beam Therapeutics' median Other Accumulated Expenses value was $12.3 million (recorded in 2022), while the average stood at $16.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 133.58% in 2023, then slumped by 72.73% in 2024.
  • Over the past 5 years, Beam Therapeutics' Other Accumulated Expenses (Yearly) stood at $4.2 million in 2020, then skyrocketed by 64.67% to $7.0 million in 2021, then skyrocketed by 76.08% to $12.3 million in 2022, then spiked by 133.58% to $28.6 million in 2023, then plummeted by 72.73% to $7.8 million in 2024.